

The role of serum and glucocorticoid inducible kinase 3 in the regulation of cell growth and malignant transformation

Maressa Anne Bruhn
Bachelor of Biotechnology (Hons)

Submitted in total fulfilment of the requirements of the degree of
Doctor of Philosophy

March 2012

School of Biological Sciences
Faculty of Science and Engineering
Flinders University

Abstract

The most well established downstream effector of phosphatidylinositol 3-kinase (PI3-K) signalling is the v-akt murine thymoma viral oncogene homolog/protein kinase B (AKT/PKB) kinase family, with many studies highlighting the critical importance of this family in normal cell physiology, including cell growth, proliferation and survival, in addition to disease states such as cancer. However, more recently AKT-independent PI3-K signalling pathways have been reported, including signalling via serum and glucocorticoid inducible kinase (SGK)3, a member of the SGK family of serine/threonine kinases. The three SGK kinases (SGK1, -2, -3) share 54% structural homology with the AKT kinases in the catalytic domain, and have shown to be similarly activated in a PI3-K-dependent manner via 3-phosphoinositide-dependent kinase 1 (PDK1). Moreover, the SGK and AKT families share many of the same downstream targets including glycogen synthase kinase 3 beta (GSK3 β), forkhead transcription factor 3a (FOXO3a), and Bcl-2 associated death promoter (BAD). The level of similarity existing between these two kinase families suggests possible functional redundancy, however studies using single isoform AKT and SGK knockout mice suggests isoform specific signalling. Furthermore distinct differences in cellular localisation between these kinases make it more likely that they each have important and specific roles.

In addition to the recent studies demonstrating that SGK3 is likely to be an important factor involved in AKT-independent malignant cell transformation, earlier studies in our laboratory demonstrated that the SGK3 isoform revealed increased transcript expression in a panel of ovarian tumour cells compared with SGK1 and SGK2, making SGK3 an interesting candidate to further characterise in both normal cell physiology and tumorigenesis.

The AKT family has been widely reported as a key downstream effector of PI3-K signalling to cell growth, thus this thesis firstly aimed to examine a possible role for SGK3 in cell growth and proliferation. Using multiple SGK3 gain-of-function epithelial and fibroblast cell lines, studies presented here revealed a strong role for SGK3 in signalling to components of the cell growth pathway, regulating macromolecular (RNA and protein) content, cell size, and regulating ribosomal-DNA (rDNA) transcription. Furthermore, using the mammalian target of rapamycin complex 1 (mTORC1) inhibitor rapamycin, these studies were also able to demonstrate that SGK3 is able to regulate cell growth in a largely mTORC1-dependent manner. Moreover, studies presented herein were also able to explore the importance of SGK3's reported endosomal localisation, demonstrating SGK3 functions optimally to influence cell growth when localised at the endosomal compartment.

Following the identification of SGK3 as an important modulator of cell growth, the second aim was to investigate the influence of SGK3 on malignant cell transformation and tumorigenesis. These studies utilised multiple pre-tumorigenic genetically defined SGK3 gain-of-function cell lines to obtain functional readouts for a variety

of well-established hallmarks of tumourigenesis, including anchorage-independent growth, cell migration and chemoresistance. Moreover, these studies incorporated the use of AKT gain-of-function cell lines in order to make comparisons between the ability of SGK3 and AKT to promote tumourigenic hallmarks. Results from these studies revealed both SGK3 and the AKT isoforms to promote anchorage-independent growth, in addition to a role for AKT in promoting cell migration, suggesting that in addition to the AKT family, SGK3 is also an important effector of malignant transformation.

Finally, the third aim of this project was to extend functional studies to global gene expression analysis, in an attempt to further define mechanisms associated with SGK3 function, and identify possible novel associations existing between SGK3 and other factors. Global gene analysis was conducted using Affymetrix genechip microarrays of all SGK3 and AKT gain-of-function cell lines used for functional studies. Through the use of two different bioinformatic approaches, including the MetaCore™ platform by GeneGo, along with Gene Set Enrichment Analysis (GSEA) from the Broad Institute, all data was interrogated to determine novel associations with SGK3, in addition to determining possible mechanisms associated with readouts observed in earlier functional analyses. These studies revealed not only known associations with SGK3, but also novel associations including demonstrating a possible role for SGK3 in the immune response, in addition to possible involvement in lysophosphatidic acid (LPA) pathway signalling. Moreover, these gene expression studies enabled comparison of differential gene regulation between both SGK3 and the AKT isoforms.

In summary, studies presented in this thesis demonstrate for the first time an important role for SGK3 in regulating cell growth via regulation of rDNA transcription, which is likely to be largely dependent on mTORC1. Furthermore, SGK3 also appears to play a critical role in the regulation of malignant transformation, which is consistent with recent reports demonstrating a role for SGK3 in AKT-independent PI3-K oncogenic signalling. Additionally, global gene expression studies allowed for the detection of novel connections with SGK3 including a role for SGK3 in the immune response. In summary this thesis furthers our understanding of the role of SGK3 in health and disease and provides an important platform that can be used as a basis for future investigations into SGK3 function.

Declaration

I certify that this thesis does not incorporate without acknowledgment any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.

Maressa A Bruhn

Preface

This thesis acknowledges the attributions from the following people for the experiments listed below:

Figure 3.3 and Figure 3.5 was completed in collaboration with Megan Astle.

Figure 3.9 was completed in collaboration with Karen Sheppard

Figure 3.14 was completed in collaboration with Karen Sheppard

Figure 4.7 was completed in collaboration with Rob Southgate

Acknowledgements

First and foremost I would like to express my sincere gratitude to my primary supervisors, Karen Sheppard and Ross Hannan for providing inspiration, enthusiasm and encouragement during the course of my PhD project, and helping me to maintain perspective, even during the more difficult days. Your patience, guidance and wisdom have been invaluable to me during both my time in the lab and the preparation of my thesis. I am eternally thankful for all the opportunities, motivation, support and understanding that you have given me during this time. Thank you.

I am also very grateful to my external supervisor Catherine Abbott for all of her important insight during my project, and all the guidance and support offered during the preparation of my thesis. I would also like to express my sincere appreciation to Rick Pearson for all of his useful advice and suggestions during the course of my PhD project.

In addition to my supervisors, a number of other important colleagues at the Peter MacCallum Cancer Centre have provided invaluable knowledge, assistance and moral support throughout the duration of my project. I am deeply indebted to Elly Tchoubrieva, Kate Hannan, Elaine Sanij, Kathy Jastrzebski, Ameer George, Rob Southgate, Megan Astle, Rachel Lee, Jane Lin and Lynette Chee for all of your kindness, constructive ideas, motivation and friendship during my project.

I would also like to thank all the staff at the Peter MacCallum Cancer Centre who have assisted me during the course of my PhD studies. I would like to give a special thanks to Ralph Rossi in the FACS core facility for all his assistance sorting my many cell lines, and Jason Ellul in the Bioinformatics core for all his assistance with the raw statistical analysis of the gene expression data.

Finally I would like to thank my family and friends for helping me to stay focused and maintain the drive and perspective to finish my work in the lab and write my thesis. More specifically to my Dad, Mum and Justin, the course of my PhD has been quite a challenging time, and I would not have been able to make it through to the end had it not been for your enduring belief in my abilities, and continuous love and support driving me forward. Words cannot express how much I appreciate you. Thank you.

I dedicate this thesis to my Dad, Mum and Justin

Publications arising from this thesis

Invited review:

Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. *Second AKT: the rise of SGK in cancer signalling*. Growth Factors 2010 Dec;28(6):394-408

Conference abstracts:

Bruhn MA, Southgate RJ, Abbott C, Pearson RB, Hannan RD, Sheppard KE. *Characterisation of the ability of SGK3 and AKT to drive markers of cell transformation in vitro*. 22nd Lorne Cancer Conference 2010.

Bruhn MA, Riddell K, Abbott C, Pearson RB, Hannan RD, Sheppard KE. *A potential role for SGK3, an AKT related kinase, in promoting cell transformation*. 20th Meeting of the European Association for Cancer Research 2008.

Bruhn MA, Riddell K, Abbott C, Pearson RB, Hannan RD, Sheppard KE. *A potential role for SGK3, an AKT related kinase, in promoting cell transformation*. 20th Lorne Cancer Conference 2008.

Bruhn MA, Riddell K, Abbott C, Pearson RB, Hannan RD, Sheppard KE. *A potential role for SGK3, an AKT related kinase, in promoting cell transformation*. 3rd Barossa Meeting Science Amongst the Vines 2007.

Table of Contents

Abstract.....	II
Declaration.....	IV
Preface.....	V
Acknowledgements.....	VI
Publications arising from this thesis.....	VII
Table of Contents	VIII
List of Figures.....	XI
List of Tables.....	XIII
Abbreviations.....	XV
1. Introduction	1
1.1 Background	1
1.2 Identification and characterisation of the three <i>sgk</i> genes.....	1
1.2.1 Discovery and cloning of the <i>sgk</i> genes.....	1
1.2.2 SGK isoform protein domain structure	2
1.2.2.1 N-terminal domain	2
1.2.2.2 Catalytic and regulatory domains.....	5
1.3 Regulation of SGK isoforms	6
1.3.1 Transcriptional Regulation.....	6
1.3.2 SGK isoform activation.....	8
1.3.2.1 Class IA and class III PI3K	9
1.3.2.2 Cellular localisation and activation	11
1.3.2.3 Phosphorylation at Serine and Threonine sites for kinase activation.....	11
1.3.3 Negative regulation of SGK isoform activity	13
1.3.4 SGK localisation	13
1.4 Biological processes regulated by SGK isoforms	14
1.4.1 SGK substrate specificity	14
1.4.2 SGK knockout mice.....	14
1.4.3 Cell proliferation	17
1.4.3.1 Regulation of cell proliferation.....	18
1.4.4 Cell growth	19
1.4.4.1 mTORC1 regulation of cell growth	22
1.4.4.2 Ribosome biogenesis.....	22
1.4.4.3 Upstream Regulation of mTORC1	24
1.4.5 Cell survival.....	25
1.4.6 Cell migration	28
1.4.7 Regulation of ion channels and transporters.....	28
1.5 SGK associated pathophysiology	30
1.5.1 Hypertension and diabetes.....	30
1.5.2 Neurodegenerative disease	31
1.6 SGK and cancer.....	32
1.6.1 Class I PI3-K and cancer.....	32
1.6.2 AKT isoforms and cancer	33
1.6.3 SGK isoforms and cancer	34
1.7 Hypothesis and Aims	36
2. Materials and Methods	37
2.1 Cell line maintenance.....	37
2.2 Generation of plasmid constructs.....	37
2.2.1 Generation of myc-tagged wildtype SGK3 expression construct	37
2.2.2 Site directed mutagenesis to generate SGK3 mutant constructs.....	38
2.2.2.1 Primer Design and PCR Reaction	38
2.2.3 Constructs	39
2.3 Generation of stable cell lines	40
2.3.1 Retrovirus production	40
2.3.2 Retroviral transduction	40
2.3.3 Stable cell line selection.....	40

2.4 Cell treatments	41
2.5 Harvesting for protein and preparation of extracts	41
2.6 Harvesting for RNA	41
2.7 Measuring protein and RNA content per cell	42
2.8 Measuring rDNA transcription	42
2.9 Synthesis of 5' externally transcribed spacer (5' ETS) ³²P-labelled antisense riboprobe	42
2.10 RNA Isolation	43
2.11 Ribonuclease protection assay	43
2.12 Cell signalling experiments	44
2.13 Immunoblotting	44
2.14 Cell proliferation assay	46
2.15 Scratch migration assay	46
2.16 Colony formation assay	46
2.17 SGK3 localisation	47
2.18 Cell cycle analysis	47
2.19 Cell death assay	47
2.20 Microarray Experiments	48
2.20.1 Microarray sample preparation	48
2.20.2 Microarray data analysis	48
2.21 Statistical Analysis	49
3. SGK3 regulation of cell growth and proliferation	50
3.1 Introduction	50
3.2 Results	51
3.2.1 Characterisation of HOSE SGK3 stable cell lines	51
3.2.2 Characterisation of BJ-hTERT SGK3 stable cell lines	61
3.2.3 Activated SGK3 increases signalling to cell growth	62
3.2.3.1 SGK3 signalling in HOSE cells	62
3.2.3.2 SGK3 signalling in BJ-hTERT cells	75
3.2.4 Activated SGK3 increases cell proliferation in non-tumourigenic ovarian epithelial cells	76
3.2.5 Activated SGK3 does not increase cell proliferation in non-tumourigenic foreskin fibroblast cells	79
3.2.6 Activated SGK3 increases cell size and key parameters of cell growth	79
3.2.7 Activated SGK3 increases rDNA transcription in epithelial and fibroblast cell lines	80
3.3 Discussion	92
3.3.1 Overview of results	92
3.3.2 SGK3 influence on cell growth signalling	97
3.3.3 Activated SGK3 increases proliferation and key parameters of cell growth	98
3.3.4 Activated SGK3 increases rDNA transcription	101
3.3.5 The influence of SGK3 localisation on cell growth and proliferation	102
3.3.6 Possible model of SGK3 signalling to cell growth	103
4. The influence of SGK3 compared with AKT on crucial hallmarks of cell transformation and tumourigenesis	106
4.1 Introduction	106
4.2 Results	107
4.2.1 Characterisation of SGK3 and AKT genetically defined pre-tumourigenic stable cell lines	108
4.2.2 Regulation of anchorage independent growth by SGK3 and AKT	114
4.2.3 AKT but not SGK3 can increase cell migration	127
4.2.4 SGK3 does not increase cell viability following treatment with chemotherapeutic agents	137
4.3 Discussion	144
4.3.1 Activated SGK3 and AKT promote anchorage independent growth	144
4.3.2 The regulation of cell migration and chemoresistance by SGK3 and AKT	152

5. Gene expression studies using microarrays of epithelial and fibroblast cell lines over-expressing SGK3 and AKT	155
5.1 Introduction	155
5.2 Methods.....	155
5.3 Results	157
5.3.1 Gene expression profiles in SGK3 transduced HOSE cells	157
5.3.1.1 Gene expression changes and pathway analysis in SGK3 WT over-expression.....	157
5.3.1.2 Gene Expression changes with SGK3 CA over-expression.....	159
5.3.1.3 Comparative analysis of changes identified between SGK WT and CA datasets.....	163
5.3.2 Gene expression profiles in AKT transduced IOSE523 cells	168
5.3.2.1 Gene expression changes with myr-AKT over-expression	168
5.3.3 Comparative analysis of gene expression differences between IOSE523-myrAKT and HOSE-SGK3CA cells.....	178
5.3.4 Differential gene expression in over-expression of SGK3 mutants in BJ-hTERT cells	182
5.3.5 Gene expression changes with myr-AKT over-expression in BJ-hTERT cells....	182
5.3.6 Comparative analysis of gene expression differences between BJ-hTERT myrAKT and BJ-hTERT SGK3CA cells.....	193
5.4 Discussion	199
5.4.1 SGK3 gene expression in ovarian epithelial cells	199
5.4.2 Comparison between SGK3 and AKT gene regulation in ovarian cell lines.....	201
5.4.3 SGK and AKT gene expression in fibroblast cells	202
5.4.4 Limitations on data interpretation	204
5.4.5 Summary	205
6. Summary and future directions	206
6.1 Overview	206
6.2 SGK3 regulates cell growth.....	207
6.3 SGK3 can promote some hallmarks of malignant cell transformation	210
6.4 SGK3 impact on global gene expression.....	212
6.5 Conclusion.....	214
Appendix I: Chapter 5 supplementary data	215
Bibliography	226

List of Figures

1. Introduction.....	1
Figure 1.1: <i>Sgk3</i> gene expression in a panel of ovarian non-tumourigenic control cells and tumourigenic epithelial cells.....	3
Figure 1.2: SGK isoform protein structure.....	4
Figure 1.3: Levels of SGK1 and SGK3 regulation.....	7
Figure 1.4: Activators and substrates of SGK1 and SGK3.....	15
Figure 1.5: The PI3-K/mTORC1 signalling network in cell growth and proliferation.....	21
Figure 1.6: Schematic representation of ribosome biogenesis.....	23
3. SGK3 regulation of cell growth and proliferation.....	50
Figure 3.1: SGK3 mutant constructs.....	53
Figure 3.2: Protein expression in stable SGK3 mutant HOSE cells.....	55
Figure 3.3: SGK3 mutant localisation in HOSE cells.....	57
Figure 3.4: Protein expression in SGK3 mutant stable BJ-hTERT cells.....	63
Figure 3.5: SGK3 mutant localisation in BJ-hTERT cells.....	65
Figure 3.6: PI3-K/AKT/mTORC1 growth signalling pathway.....	71
Figure 3.7: SGK3 increases signalling to cell growth in HOSE cells.....	73
Figure 3.8: Activated SGK3 increases signalling to cell growth in BJ-hTERT cells.....	77
Figure 3.9: SGK3 increases cell proliferation in HOSE cells.....	81
Figure 3.10: SGK3 does not increase cell proliferation in BJ-hTERT cells.....	83
Figure 3.11: Exponentially growing cell size is increased by activated SGK3 in both HOSE and BJ-hTERT cells.....	85
Figure 3.12: Activated SGK3 increases macromolecular content and cell size in HOSE cells.....	87
Figure 3.13: Activated SGK3 increases macromolecular content and cell size in BJ-hTERT cells.....	89
Figure 3.14: Activated SGK3 increases rDNA transcription in HOSE cells.....	93
Figure 3.15: Activated SGK3 increases rDNA transcription in BJ-hTERT cells.....	95
Figure 3.16: Proposed model of SGK3 signalling to cell growth and proliferation.....	99
4. The influence of SGK3 compared with AKT on crucial hallmarks of cell transformation and tumourigenesis.....	106
Figure 4.1: Genetically defined cell models of malignant cell transformation.....	109
Figure 4.2: SGK3 and AKT mutant stable protein expression in BJ-LST cells.....	111
Figure 4.3: SGK3 and AKT mutant stable protein expression in IOSE523 cells.....	115
Figure 4.4: SGK3 increases anchorage independent growth in BJ-LST cells.....	119
Figure 4.5: AKT increases anchorage independent growth in BJ-LST cells.....	121
Figure 4.6: SGK3 does not increase anchorage independent growth in IOSE523 cells... ..	123
Figure 4.7: AKT increases anchorage independent growth in IOSE523 cells.....	125
Figure 4.8: SGK3 does not increase anchorage independent growth in HOSE cells.....	129
Figure 4.9: SGK3 does not increase cell migration in BJ-LST cells.....	131
Figure 4.10: AKT increases cell migration in BJ-LST cells.....	133
Figure 4.11: SGK3 does not increase cell migration in HOSE cells.....	135
Figure 4.12: AKT does not increase cell migration in IOSE523 cells.....	139
Figure 4.13: The effect of SGK3 and AKT on cell viability following cisplatin treatment.....	141
Figure 4.14: The effect of SGK3 and AKT on cell viability following taxol treatment.....	145
Figure 4.15: The effect of SGK3 and AKT on cell viability following vincristine treatment.....	147
5. Gene expression studies using microarrays of epithelial and fibroblast cell lines over-expressing SGK3 and AKT.....	155
Figure 5.1: HOSE SGK3 WT compared with HOSE pMIG gene expression data.....	158
Figure 5.2: HOSE SGK3 CA compared with HOSE pMIG gene expression data.....	162
Figure 5.3: Venn Diagram showing common differentially regulated genes in HOSE-SGK3 CA Vs HOSE-SGK3 WT.....	166
Figure 5.4: Venn Diagram showing common differentially regulated genes in HOSE-SGK3 CA vs HOSE-SGK3 WT.....	166
Figure 5.5: IOSE523-myrAKT1 compared with IOSE523-pMIC gene expression data.....	169

Figure 5.6: IOSE523-myrAKT2 gene expression data compared with IOSE523-pMIC gene expression data.	173
Figure 5.7: IOSE523-myrAKT3 gene expression data compared with IOSE523-pMIC gene expression data.	176
Figure 5.8: Venn diagram showing common differentially regulated genes between all three IOSE523-myrAKT cell lines.....	180
Figure 5.9: Venn diagram showing common differentially regulated genes between IOSE523-myrAKT1 and HOSE SGK3CA cell lines.....	180
Figure 5.10: Venn diagram showing common differentially regulated genes between IOSE523-myrAKT2 and HOSE SGK3CA cell lines.....	181
Figure 5.11: Venn diagram showing common differentially regulated genes between IOSE523-myrAKT3 and HOSE SGK3CA cell lines.....	181
Figure 5.12: BJ-hTERT SGK3 CA gene expression data compared with BJ-hTERT pMIC gene expression data.....	183
Figure 5.13: BJ-hTERT myrAKT1 gene expression data compared with BJ-hTERT pMIC gene expression data.....	186
Figure 5.14: BJ-hTERT myrAKT2 gene expression data compared with BJ-hTERT pMIC gene expression data.....	189
Figure 5.15: BJ-hTERT myrAKT3 gene expression data compared with BJ-hTERT pMIC gene expression data.....	192
Figure 5.16: Venn diagram showing common differentially regulated genes between all three BJ-hTERT-myrAKT cell lines.....	196
Figure 5.17: Venn diagram showing common differentially regulated genes between BJ-hTERT SGK3CA and BJ-hTERT myrAKT1 cell lines.....	196
Figure 5.18: Venn diagram showing common differentially regulated genes between BJ-hTERT SGK3CA and BJ-hTERT myrAKT2 cell lines.....	197
Figure 5.19: Venn diagram showing common differentially regulated genes between BJ-hTERT SGK3CA and BJ-hTERT myrAKT3 cell lines.....	197
Figure 5.20: Venn diagram showing common differentially regulated genes between all genes commonly regulated by all three BJ-hTERT myrAKT isoforms (BJ-hTERT-myrAKT) and BJ-hTERT SGK3CA.....	198

List of Tables

1. Introduction.....	1
Table 1.1: SGK isoform regulation and activation summary	16
2. Materials and Methods.....	37
Table 2.1: Mutations and primer sequences used for site directed mutagenesis	39
Table 2.2: Inhibitor concentrations	41
Table 2.3: Antibodies used for immunoblotting	45
Table 2.4: Antibodies used for SGK3 localisation	47
Table 2.5: Cytotoxic agents used for cell death assays	48
5. Gene expression studies using microarrays of epithelial and fibroblast cell lines over-expressing SGK3 and AKT	155
Table 5.1: HOSE SGK3 WT compared with HOSE pMIG gene expression data.....	158
Table 5.2: HOSE SGK3 WT Top 10 GeneGO pathways identified using a FC 0, p-val <0.05.....	160
Table 5.3: HOSE SGK3 WT Top 10 GeneGO pathways identified using a FC >2, p-val <0.05.....	160
Table 5.4: Top 20 ranked GSEA gene sets enriched in HOSE-SGK3 WT.	161
Table 5.5: HOSE SGK3 CA compared with HOSE pMIG gene expression data.....	162
Table 5.6: All HOSE SGK3 CA GeneGO pathways identified using a FC 0, p-val <0.05.....	164
Table 5.7: All HOSE SGK3 CA GeneGO pathways identified using a FC >2, p -val <0.05.....	164
Table 5.8: Top 20 ranked GSEA gene sets enriched in HOSE-SGK3 CA.....	165
Table 5.9: Differential expression between HOSE SGK3WT and HOSE SGK3CA cell lines.	167
Table 5.10: IOSE523-myrAKT1 compared with IOSE523-pMIC gene expression data.....	169
Table 5.11: IOSE523-myrAKT1 GeneGO pathways identified using FC 0, p-val <0.05.....	171
Table 5.12: IOSE523-myrAKT1 GeneGO pathways identified using FC >2, p-val <0.05... 171	
Table 5.13: Top 20 ranked GSEA gene sets enriched in IOSE523-myrAKT1.....	172
Table 5.14: IOSE523-myrAKT2 compared with IOSE523-pMIC gene expression data.....	173
Table 5.15: IOSE523-myrAKT2 GeneGO pathways identified using FC 0, p-val 0.05.....	174
Table 5.16: IOSE523-myrAKT2 GeneGO pathways identified using FC >2, p-val 0.05.....	174
Table 5.17: Top 20 ranked GSEA gene sets enriched in IOSE523-myrAKT2.....	175
Table 5.18: All IOSE523-myrAKT3 compared with IOSE523-pMIC gene expression data.....	176
Table 5.19: All IOSE523-myrAKT3 GeneGO pathways identified using FC >2, P-val 0.05.	177
Table 5.20: Top 20 ranked gene sets enriched in IOSE523-myrAKT3.	179
Table 5.21: All BJ-hTERT SGK3 CA compared with BJ-hTERT-pMIG gene expression data.....	183
Table 5.22: BJ-hTERT SGK3 CA GeneGO pathways identified using FC 0, P-val <0.05. 184	
Table 5.23: All BJ-hTERT SGK3 CA GeneGO pathways identified using FC >2, P-val <0.05.	184
Table 5.24: BJ-hTERT myrAKT1 compared with BJ-hTERT-pMIC gene expression data. 186	
Table 5.25: BJ-hTERT myrAKT1 GeneGO pathways identified using FC 0, p-val <0.05... 187	
Table 5.26: BJ-hTERT myrAKT1 GeneGO pathways identified using FC >2, p-val <0.05. 187	
Table 5.27: Top 20 ranked GSEA gene sets enriched in BJhTERT-myrAKT1.....	188
Table 5.28: BJ-hTERT myrAKT2 compared with BJ-hTERT-pMIC gene expression data..189	
Table 5.29: BJ-hTERT myrAKT2 GeneGO pathways identified using FC 0, p-val <0.05... 190	
Table 5.30: BJ-hTERT myrAKT2 GeneGO pathways identified using FC >2, p-val <0.05. 190	
Table 5.31: Top 20 ranked GSEA gene sets enriched in BJhTERT-myrAKT2.....	191
Table 5.32: BJ-hTERT myrAKT3 compared with BJ-hTERT-pMIC gene expression data. 192	
Table 5.33: BJ-hTERT myrAKT3 GeneGO pathways identified using FC 0, p-val <0.05... 194	
Table 5.34: BJ-hTERT myrAKT3 GeneGO pathways identified using FC >2, p-val <0.05. 194	
Table 5.35: Top 20 ranked GSEA gene sets enriched in BJhTERT-myrAKT3.....	195
Table 5.36: Differential expression between BJ-hTERT SGK3 and BJ-hTERT myrAKT cell lines.....	198

Appendix I: Chapter 5 supplementary data	215
Table S.1: HOSE SGK3 WT remaining GeneGO pathways. Identified using a FC 0, p-val <0.05.....	215
Table S.2: HOSE SGK3 WT remaining GeneGO pathways. Identified using a FC >2, p-val <0.05.....	216
Table S.3: IOSE523-myrAKT1 remaining GeneGO pathways. Identified using FC 0, p-val <0.05.....	217
Table S.4: IOSE523-myrAKT1 remaining GeneGO pathways. Identified using FC >2, p-val <0.05.....	218
Table S.5: IOSE523-myrAKT2 remaining GeneGO pathways. Identified using FC 0, p-val 0.05.....	219
Table S.6: IOSE523-myrAKT2 remaining GeneGO pathways. Identified using FC >2, p-val 0.05.....	219
Table S.7: BJ-hTERT SGK3 CA remaining GeneGO pathways. Identified using FC 0, p-val <0.05.....	220
Table S.8: BJ-hTERT myrAKT1 remaining GeneGO pathways. Identified using FC 0, p-val <0.05.....	222
Table S.9: BJ-hTERT myrAKT1 remaining GeneGO pathways. Identified using FC >2, p-val <0.05.....	223
Table S.10: BJ-hTERT myrAKT2 GeneGO pathways. Identified using FC 0, p-val <0.05.....	225
Table S.11: BJ-hTERT myrAKT2 remaining GeneGO pathways. Identified using FC >2, p-val <0.05.....	225

Abbreviations

Amino acid abbreviations

Ala	A	Alanine
Arg	R	Arginine
Asn	N	Asparagine
Asp	D	Aspartic acid (Aspartate)
Cys	C	Cysteine
Gln	Q	Glutamine
Glu	E	Glutamic acid (Glutamate)
Gly	G	Glycine
His	H	Histidine
Ile	I	Isoleucine
Leu	L	Leucine
Lys	K	Lysine
Met	M	Methionine
Phe	F	Phenylalanine
Pro	P	Proline
Ser	S	Serine
Thr	T	Threonine
Trp	W	Tryptophan
Tyr	Y	Tyrosine
Val	V	Valine
Asx	B	Aspartic acid or Asparagine
Glx	Z	Glutamine or Glutamic acid
Xaa	X	Any amino acid

Other abbreviations

-/-	knockout
+/-	heterozygous
∞	affinity
Ω	ohms
μ F	microfarad
μ g	micrograms
μ l	microlitres
μ M	micromolar
4EBP1	eukaryotic initiating factor 4E (eIF4E)-binding protein 1
5'ETS	5' externally transcribed spacer region
5'TOP	5' oligopyrimidine tract
AGC	Cyclic AMP-dependent protein kinase, cyclic GMP-dependent protein kinase and protein kinase C family
AIP4	atrophin-1 interacting protein 4
AKT	v-akt murine thymoma viral oncogene homolog
AKTi	AKT inhibitor
AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
APC	adenomatous polyposis coli
APOD	apolipoprotein D
AR	androgen receptor
ASCT2	sodium-dependent neutral amino acid transporter type 2
ATF6	activating transcription factor 6
ATM	ataxia telangiectasia mutated

ATP	adenosine triphosphate
ATR	ataxia telangiectasia and Rad3 related
BAD	Bcl-2 associated death promoter
BBC3	bcl-2-binding component 3
Bcl-2	B-cell leukemia/lymphoma 2
BH3	Bcl-2 homology domain 3
BIM	bcl-2-like protein 11
BMK-1	big MAP kinase
BMP7	bone morphogenetic protein
B-Raf	v-raf murine sarcoma viral oncogene homolog B1
BSA	bovine serum albumin
C3	complement component 3
CA	constitutively active
CaCl ₂	calcium chloride
CaMKK	calmodulin-dependent protein kinase kinase
cAMP	cycline adenosine monophosphate
CCND1	cyclin D1
CD36	cluster of differentiation 36
CDC42	cell division cycle 42 (GTP binding protein, 25kDa)
CDK	cyclin dependent kinases
cDNA	complementary DNA
CFTR	the cystic fibrosis transmembrane conductance regulator Cl ⁻ channel
Chk1	checkpoint kinase 1
CHIP	C-terminus of Hsc (heat shock cognate protein) 70-interacting protein
CIP	cyclin dependent kinase (CDK)-inhibitor
CISK	cytokine independent survival kinase
CIC-Ka	renal and inner ear Cl ⁻ channel
CIC2	ubiquitous Cl ⁻ channel
CLDN1	caludin-1
CO ₂	carbon dioxide
COL14A1	collagen type XIV alpha 1
CPM	counts per minute
CRAC	Orai1 the pore-forming unit of Ca ²⁺ -release-activated- Ca ²⁺ channel
CREB	camp response element binding protein
c-Rel	reticuloendotheliosis viral oncogene homolog
CST	cell signaling technology
C-terminal	carboxyl-terminal
CXCL12	chemokine (C-X-C motif) 12
CXCR4	chemokine (C-X-C motif) receptor 4
dATP	deoxyadenosine triphosphate
DAPI	4',6-diamidino-2-phenylindole
DDIT4	DNA-damage-inducible transcript 4
DEPC	diethyl pyrocarbonate
DISC	death-inducing signalling complex
DMEM	Dulbecco's modified eagle medium
DMSO	dimethyl sulphoxide
DN	dominant negative
DNA	deoxy ribonucleic acid
dNTPs	deoxyribonucleotide triphosphates
DSP	desmoplakin
DTT	dithiothreitol
EAAT1/2/3/4/5	excitatory amino-acid transporters
ECM	extracellular matrix

EDTA	ethylenediaminetetraacetic acid
EEA1	early endosomal antigen 1
EGF	epidermal growth factor
EGFR	epidermal growth factor receptor
eIF4E	eukaryotic initiating factor 4E
eIF4G	eukaryotic initiation factor 4G
EMT	epithelial-mesenchymal transition
ENac	epithelial sodium channel
ENPP2	ectonucleotide pyrophosphatase/phosphodiesterase family member 2/Autotaxin
ER	endoplasmic reticulum
ERK	extracellular signal-related kinase
ES	embryonic stem cells
ETS	externally transcribed spacer
FACS	fluorescence-activated cell sorting
FAK	focal adhesion kinase
FasL	Fas Ligand
FAST	forkhead activin signal transducer
FBS	foetal bovine serum
Fbw7	of F-box/WD repeat containing protein 7
FC	fold change
FDR	false discovery rate
FGF	fibroblast growth factor
fL	femtolitres
FLI-1	flightless-1
FOXO3a	Forkhead transcription factor
FSH	follicle stimulating hormone
FXR	farnesoids
FYVE	Fab1/YOTB/2K632.12/Vac1/EEA1
G β L	G protein β -subunit-like protein
GFP	green fluorescent protein
GILZ1	glucocorticoid-induced leucine zipper protein-1
GJA5	connexin 40
GLUT	glucose transporter
GM-CSF	granulocyte/macrophage colony stimulating factor
GPCR	G protein coupled receptors
GR	glucocorticoid receptor
GRE	glucocorticoid response element
GSEA	gene set enrichment analysis
GSK3 β	glycogen synthase kinase β
GTC	guanidine thiocyanate
HA	haemagglutinin
HD	Huntington's disease
HDAC	histone deacetylase
HEK293	human embryonic kidney 293 cells
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HER2	human epidermal growth factor receptor 2
HERG	human ether-a-go-go
HGF	hepatic growth factor
HIF	hypoxia inducible factor
HM	hydrophobic motif
HMEC	human mammary epithelial cells
H-Ras	v-Ha-ras Harvey rat sarcoma viral oncogene homolog
HOSE	human ovarian surface epithelial
HPV	human papilloma virus

Hr	hour
HRP	horseradish peroxidase
HSF	heat shock factor
Hsp90	heat shock protein 90
hVps34	human vacuolar sorting protein 34
IFI6	interferon alpha-inducible protein 6
IFN	interferon
IGF	insulin-like growth factor
IGFR	insulin growth factor receptor
IKK β	I kappa B kinase beta
IL-1	interleukin 1
IL-2	interleukin 2
IL-3	interleukin 3
IL-6	interleukin 6
ILK	integrin-linked kinase
IOSE523	immortalised ovarian surface epithelial 523
IRES	internal ribosome entry site
ISGF3	interferon-stimulated gamma factor 3
ITS	internally transcribed spacer
JNK	c-Jun N-terminal kinase
JUP	plakoglobin
K ⁺	potassium
KCNQ1/KCNE	cardiac and epithelial K ⁺ channels
KCNQ4	inner ear K ⁺ channels
KD	kinase dead
KO	knockout
kV	kilovolts
KV1.3, KV1.5	voltage-gated K ⁺ channels and Kv4.3
kDa	kilodalton
KIP	kinase inhibitor proteins
LAMC1	laminin 1
LB	luria broth
LIPC	hepatic triacylglycerol lipase
LIPE	endothelial lipase
LKB1	liver kinase B1
LPA	lysophosphatidic acid
LPAR3	lysophosphatidic acid receptor 3
LPXN	Leupaxin
LT	simian virus 40 large T antigen
LTR	long terminal repeat
M	Molar (with respect to solution concentrations)
MAPK	mitogen activated protein kinase
MAPK3	mitogen-activated protein kinase 3
MBD2	methy-CpG binding domain protein 2
Mdm2	murine double minute 2
MEFs	mouse embryonic fibroblasts
MEK1/2	mitogen-activated protein kinase kinase 1/2
MEKK3	mitogen-activated protein kinase kinase kinase 3
Min	minute
MKK3	mitogen-activated protein kinase kinase 3
ml	millilitres
MLLT11	myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog Drosophila) translocated to 11
mLST8	mammalian lethal with sec thirteen

mm	millimetre
MMP	matrix metalloproteinase
MQ	millique
mRNA	messenger RNA
mSin1	mammalian stress activated protein kinase-interacting protein
MSCV	murine stem cell virus
MSigDB	Molecular signatures database
MTM1	myotubularin 1
mTOR	mammalian target of rapamycin
mTORC1	mammalian target of rapamycin complex 1
mTORC2	mammalian target of rapamycin complex 2
MTT	thiazolyl blue tetrazolium bromide
Myr	myristolated
Na ⁺	sodium
NaAc	sodium acetate
NaCl	sodium chloride
NaDC-1	Na ⁺ -dicarboxylate cotransporter
Na ₂ HPO ₄	disodium hydrogen phosphate
NaPiIb	Na ⁺ dependent Pi cotransporter
NFκB	nuclear factor κB
NHE3	sodium-hydrogen antiporter 3
NHERF2	Na ⁺ /H ⁺ exchanger regulating factor 2
NLS	nuclear localisation signal
nM	nanomolar
NP-40	nonyl phenoxypolyethoxylethanol
Nt	nucleotide
N-terminal	amino-terminal
P	phosphorylated
PAS	phospho-AKT substrate
PBS	phosphate buffered saline
PCR	polymerase chain reaction
PDGF	platelet derived growth factor
PDGFR	platelet derived growth factor receptor
PDK1	3-phosphoinositide-dependent kinase 1
pg	picograms
PH	Pleckstrin homology
PI	propidium iodide
PI3-K	phosphatidylinositol 3-kinase
PIF	PDK1 interacting fragment
PIKK	phosphoinositide 3-kinase-related kinase
PIP2	phosphatidylinositol-3,4-biphosphate
PIP3	phosphatidylinositol-3,4,5-triphosphate
PIPES	piperazinethanesulfonic acid
PKA	protein kinase A
PKB	protein kinase B
PKC	protein kinase C
PKG	protein kinase G
PLA2	phospholipase A2
PLAU	plasminogen activator urokinase
PMAIP1	phorbol-12-myristate-13-acetate-induced protein 1
PMCC	peter maccallum cancer centre
pMIG	MSCV-IRES-GFP
pMIC	MSCV-IRES-Cherry
PMSF	phenylmethylsulfonyl fluoride
Pol I	RNA polymerase I

Pol II	RNA polymerase II
Pol III	RNA polymerase III
PP2A	protein phosphatase 2A
PPAR γ	peroxysome proliferator activator receptor gamma
PRAS40	proline rich AKT substrate of 40 kDa
PRICKLE2	prickle homolog 2 (Drosophila)
PTEN	phosphatase and tensin homolog deleted on chromosome 10
PtdIns	inositol-containing lipids
PtdIns(3)P	phosphatidylinositol 3-phosphate
PtdIns(4)P	PtdIns-4-phosphate
PtdIns(4,5)P ₂	PtdIns-4,5-bisphosphate
PtdIns(3,4,5)P ₃	phosphatidylinositol 3,4,5-trisphosphate
p-val	P-value
PVDF	polyvinylidene fluoride
PX	phox homology
Rac1	Ras-related C3 botulinum toxin substrate 1
Rb	retinoblastoma protein
rDNA	ribosomal DNA
RFP	cherry fluorescent protein
Rheb	Ras homolog enriched in brain
RLB	rac lysis buffer
RNA	ribonucleic acid
RNAi	interfering RNA
r-proteins	ribosomal proteins
ROMK1	renal outer medullary K ⁺ channel
RPA	ribonuclease protection assay
rpS6	ribosomal protein S6
rRNA	ribosomal RNA
RTK	receptor tyrosine kinases
RXR	retinoids
S6K1	S6 kinase 1
SAPK	stress-activated protein kinase
SCN5A	cardiac voltage gated Na ⁺ channel
SDS	sodium dodecyl sulphate
SDS-PAGE	sodium dodecyl sulphate – polyacrylamide gel
SEM	standard error of the mean
SERPINE2	serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 2
SGK	serum and glucocorticoid inducible kinase
SGLT1	Na ⁺ -glucose cotransporter
SH2	src homology domain
SILAC	stable isotope labelling by amino acids in cell culture
siRNA	small interfering RNA
SLC14A1	solute carrier family 14 (urea transporter) member 1 (Kidd blood group)
SLC6A8	sodium- and chloride-dependent creatine transporter 1
SLC6A15	solute carrier family 6 (neutral amino acid transporter) member 15
SMAD	mothers against decapentaplegic homolog
SMIT1	hypertonicity-activated myo-inositol transporter
SN1	system N1
SOC	super optimal broth with catabolite repression
SOX4	SRY (sex determining region Y)-box 4
SPARC	osteonectin
SREBP	sterol regulatory element binding protein
ST	simian virus 40 small T antigen

STAT	signal transducers and activators of transcription
SV40	simian virus 40
TBS	tris buffered saline
TE	tris-EDTA
TGF- β	transforming growth factor beta
TRPV5	renal epithelial Ca ²⁺ channel
TSC1	tuberous sclerosis complex 1
TSC2	tuberous sclerosis complex 2
UBF	upstream binding factor/upstream binding transcription factor RNA polymerase I
UTR	untranslated region
UVB	ultraviolet B
VDR	vitamin D receptor
VEGF	vascular endothelial growth factor
WNK	with no lysine K
WSB	western solubilisation buffer